Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer [Phase 1]
A phase 1 trial evaluating N-803 in combination with pembrolizumab and enfortumab vedotin for urothelial cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-10-21Clinical Trial Update: Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial [Phase 2]
The NERA trial, a Phase 2 study of erdafitinib with or without atezolizumab in localized bladder cancer patients ineligible for cisplatin ch…
-
CLINICAL_TRIALS withdrawal · 2025-06-15Clinical Trial Update: Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer [Phase 1, Phase 2]
This entry notes that the Phase 1/Phase 2 trial of copanlisib plus avelumab as maintenance therapy for advanced urothelial carcinoma has bee…
-
CLINICAL_TRIALS withdrawal · 2025-04-09Clinical Trial Update: Study of OB-002 in Patients With Refractory Metastatic Cancer [Phase 1]
Phase 1 study of OB-002 in various metastatic cancers has been withdrawn from clinical trials.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy [Phase 1, Phase 2]
A Phase 1/2 trial of the NANT Urothelial Cancer Vaccine for urothelial carcinoma in patients who progressed after chemotherapy and PD-1/PD-L…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition [Phase 2]
Phase 2 trial assessing Vactosertib with Durvalumab for urothelial carcinoma that had progressed on checkpoint inhibitors has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2024-09-27Clinical Trial Update: Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) [Phase 2]
This document reports the withdrawal of a Phase 2 trial evaluating avelumab in combination with tuvusertib for advanced urothelial carcinoma…
-
CLINICAL_TRIALS withdrawal · 2024-08-01Clinical Trial Update: Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy [Phase 2]
This Phase II trial of lurbinectedin plus avelumab as switch-maintenance first-line therapy for metastatic urothelial carcinoma has been wit…
-
CLINICAL_TRIALS withdrawal · 2024-07-05Clinical Trial Update: Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma [Phase 1]
A Phase 1 study of magrolimab in combination with cytotoxic chemotherapy for advanced urothelial carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-19Clinical Trial Update: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma [Phase 2]
Withdrawn Phase 2 trial evaluating second-line docetaxel plus ASA-404 for advanced urothelial carcinoma.
-
CLINICAL_TRIALS withdrawal · 2014-04-29Clinical Trial Update: Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma [Phase 2]
Phase 2 trial of trebananib (AMG 386) in combination with docetaxel for advanced urothelial carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2008-09-26Clinical Trial Update: Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma [Phase 2]
A Phase 2 chemoprevention trial for uremia-associated urothelial carcinoma sponsored by National Taiwan University Hospital has been withdra…